Published in J Neurol Sci on May 01, 2000
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 1.61
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. PLoS One (2015) 0.81
Recent clinical trials and future therapies. J Neurol (2008) 0.79
Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clin Exp Immunol (2015) 0.76
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 5.59
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Cytomegalovirus and Rasmussen's encephalitis. Lancet (1990) 2.96
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain (1989) 2.59
Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain (1991) 2.11
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocytic cell line. J Immunol (1988) 2.01
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production. J Exp Med (1984) 1.92
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain (1999) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85
Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology (2010) 1.85
Paraplegia following coeliac plexus block. Pain (1993) 1.85
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol (2001) 1.75
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler (2012) 1.74
The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72
Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol (1994) 1.72
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler (2008) 1.70
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2011) 1.68
A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64
Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology (2007) 1.62
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain (2003) 1.60
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology (1998) 1.58
Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol (2011) 1.58
Denaturing gradient gel electrophoresis analysis of the 16S rRNA gene V1 region to monitor dynamic changes in the bacterial population during fermentation of Italian sausages. Appl Environ Microbiol (2001) 1.57
Electrophysiological and MRI evaluation of neurological involvement in Behçet's disease. J Neurol Neurosurg Psychiatry (1989) 1.54
Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol (1999) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae. Int J Food Microbiol (2001) 1.52
Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry (2001) 1.51
In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain (2007) 1.48
A population-based study of multiple sclerosis in twins: update. Ann Neurol (1993) 1.46
Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol (1998) 1.44
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology (2010) 1.44
Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry (2000) 1.43
IFCN standards for digital recording of clinical EEG. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol (1998) 1.43
Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler (2012) 1.42
The "mirror-neuron system" in MS: A 3 tesla fMRI study. Neurology (2007) 1.42
Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol (1999) 1.42
Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage (2002) 1.41
Neurodegeneration in the course of Langerhans cell histiocytosis. Neurol Sci (2011) 1.40
HTLV-1 associated myelopathy in Canada. Can J Neurol Sci (1989) 1.40
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology (2000) 1.39
Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment. Ital J Neurol Sci (1996) 1.39
Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy. Cancer J Sci Am (1997) 1.38
A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology (1995) 1.38
Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol (2001) 1.29
Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol (1999) 1.28
Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain (1996) 1.27
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology (2010) 1.27
Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol (1999) 1.27
Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology (2010) 1.27
Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. Neurology (2006) 1.26
The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain (1991) 1.25
Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood (2001) 1.24
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (1984) 1.24
Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency. Neurology (2004) 1.22
Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis (1986) 1.22
The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology (2010) 1.22